An experimental drug made from a marijuana plant to treat seizures associated with two rare forms of epilepsy affecting children has been approved by Food and Drug Administration staff. Photo by Atomazul/Shutterstock

Food and Drug Administration (FDA) Commissioner Scott Gottlieb arrives to testify on the FDA FY2019 Budget during a House Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee hearing on Capitol Hill in Washington, D.C. on Tuesday. Photo by Kevin Dietsch/UPI | License Photo

April 17 (UPI) -- Staff members at the Food and Drug Administration have approved an experimental drug made from a marijuana plant that is used to treat seizures associated with two rare forms of epilepsy affecting children.

The FDA briefing document, released Tuesday, was prepared before an advisory committee meeting scheduled for Thursday. The next step is for the FDA commissioners to approve the drug.


Epidiolex, manufactured by GW Pharmaceuticals, was studied to treat Dravet syndrome and Lennox-Gastaut syndrome, which are rare forms of epilepsy most resistant to other treatment that affect children 2 years old and older.

The drug is given as a syrup with strawberry flavoring and includes cannabidiol, an active ingredient found in marijuana. But it contains less than 0.1 percent of tetrahydrocannabinol, or THC, the psychoactive substance in marijuana that makes users high.

"Although CBD is a cannabinoid, it shares almost none of the pharmacologic features of the prototypical cannabinoid," the staff wrote.

The staff noted that the drug "has significantly less abuse potential" than two other forms of cannibas: THC given as 2 doses of dronabinol or a single dose of alprazola, or ALZ.

GW's drug "reduces seizure frequency in patients with drug-resistant LGS or DS while maintaining a predictable and manageable safety profile," according to FDA staff. The findings were based on three clinical studies.

The acceptable safety risks included liver injury, which it said can be managed and monitored.

Another GW Pharma drug, Sativex, derived from the cannabis plant, has been approved in numerous countries outside of the United States to treat muscle contraction in multiple sclerosis patients, according to the company website.

"Epidiolex, if approved, will mark a sea change in the acceptability of cannabinoids as therapy," GW Pharma Chief Executive Officer Justin Gover said in an interview with Bloomberg earlier this month.

Some drugs made from synthetic cannabinoids have been approved by the FDA, including Insys Therapeutics Inc.'s Syndros for loss of appetite in people with AIDS and nausea caused by chemotherapy. Insys also is developing a cannabidiol oral solution for a severe type of epileptic seizure known as infantile spasms.

Medical marijuana has been approved in 29 states and Washington, D.C., according to ProCon.org.